Search Videos and More
News
Dana-Farber Study Highlights the Need for Faster, More Accurate Diagnosis of Rare Cancer
A new study from Dana-Farber Cancer Institute finds that patients with NUT carcinoma (NC), an aggressive squamous cell lung or head and neck cancer, often face delays in diagnosis—delays that can prevent them from receiving the right treatment or joining clinical trials.
News
Dana-Farber researchers present findings at 2025 San Antonio Breast Cancer Symposium
Physician scientists from Dana-Farber Cancer Institute will present more than 50 research studies at the 48th annual San Antonio Breast Cancer Symposium, December 9-12.
News
Dana-Farber Research Opens the Door to Finding More Effective Treatments for Ewing Sarcoma
In 2014, Dana-Farber pediatric oncologist Brian Crompton, MD, discovered that a gene called STAG2 is mutated in about 15 percent of patients with Ewing sarcoma, a form of bone cancer that largely occurs in children and adolescents.
News
Dana-Farber Research Supports FDA Approval of Sevabertinib for HER2-Mutant Lung Cancer
The US Food and Drug Administration has approved sevabertinib, an oral targeted therapy for adult patients with non-small-cell lung cancer (NSCLC) whose tumors harbor certain HER2 (also called ERBB2) mutations and who have previously received chemotherapy or immunotherapy.
News
Dana-Farber Cancer Institute Faculty Among World's Most Highly Cited Researchers
Dana-Farber Cancer Institute is proud to announce that 38 of its researchers have been named to the Highly Cited Researchers list of 2025, released by the Institute for Scientific Information at Clarivate.
News
Dana-Farber Research Points to Potential Gene Therapy Improvements
Viruses aren’t thought of as living beings. Rather, they are collections of genetic instructions that hijack the replication machinery of living cells to perpetuate themselves.
News
Three Ways Research Could Improve Pancreatic Cancer Treatment
Pancreatic cancer has long been difficult to detect and treat. Dana-Farber experts in the Hale Family Center for Pancreatic Cancer Research, however, are working to change that with research efforts in three key areas that are poised to advance early detection, early intervention, and treatment of the disease.
News
Menin Inhibitors: A New Class of Anti-Leukemic Agents
A new and potentially broadly applicable class of anti-leukemic agents has arrived on the scene due to preclinical work done in the laboratory of Scott Armstrong, MD, PhD, of Dana-Farber Cancer Institute in collaboration with members of the Adult Leukemia Program within Medical Oncology at Dana-Farber led by Richard Stone, MD, Chief of Staff.
News
Dana-Farber Research Uncovers Potential Targeted Therapy for Endometrial Cancer
Jessica St. Laurent, MD, was sure something had gone wrong. The results of an experiment she’d run showed that the cancer cells she was studying had abnormally high levels of a specific collection of proteins of interest to her team.
News
New Research Sheds Light on Why Tamoxifen May Lead to Higher Risk of Uterine Cancer
Since its introduction in the 1970s, tamoxifen has significantly improved survival rates for millions of patients with estrogen receptor–positive breast cancer.
News
Dana-Farber Researchers Find Less Treatment May be More in Mantle Cell Lymphoma
For a long time, the standard treatment for younger patients with newly diagnosed mantle cell lymphoma involved intensive chemotherapy, called induction therapy, followed by autologous stem cell transplant (ASCT, where the patient’s own stem cells are used), followed by maintenance therapy to help keep the cancer from coming back.
News
New Strategy for Small Cell Lung Cancer Treatment Emerges from Dana-Farber Science
Dana-Farber researchers have provided the mechanistic and preclinical evidence needed to support a clinical trial of a new class of drugs called direct cyclin inhibitors in patients with a range of cancers.